IQVIA (United States)

The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment

Melissa Haendel, Christopher G. Chute, Tellen D. Bennett et al.

2020 · 573 Zit.

Characterizing the Clinical Adoption of Medical AI Devices through U.S. Insurance Claims

Kevin Wu, Eric Q. Wu, Brandon Theodorou et al.

2023 · 78 Zit.

FLANNEL (Focal Loss bAsed Neural Network EnsembLe) for COVID-19 detection

Zhi Qiao, Austin Bae, Lucas M. Glass et al.

2020 · 31 Zit.

Optimizing clinical trials recruitment via deep learning

Jelena Gligorijević, Djordje Gligorijevic, Martin Pavlovski et al.

2019 · 30 Zit.

Toward responsible AI governance: Balancing multi-stakeholder perspectives on AI in healthcare

Leon Rozenblit, Amy Price, Anthony Solomonides et al.

2025 · 10 Zit.

FRAMM: Fair ranking with missing modalities for clinical trial site selection

Brandon Theodorou, Lucas M. Glass, Cao Xiao et al.

2024 · 10 Zit.

Designing Equitable Health Care Outreach Programs From Machine Learning Patient Risk Scores

Christopher A. Hane, Melanie Wasserman

2022 · 7 Zit.

Characterizing the clinical adoption of medical AI through U.S. insurance claims

Kevin Wu, Eric Q. Wu, Brandon Theodorou et al.

2023 · 4 Zit.

A perspective for adapting generalist AI to specialized medical AI applications and their challenges

Zifeng Wang, Hanyin Wang, Benjamin Danek et al.

2025 · 3 Zit.

Towards responsible artificial intelligence in healthcare—getting real about real-world data and evidence

Eileen Koski, Amar K. Das, Pei-Yun Hsueh et al.

2025 · 3 Zit.

Core Concepts in Pharmacoepidemiology: Principled Use of Artificial Intelligence and Machine Learning in Pharmacoepidemiology and Healthcare Research

Kathryn Rough, Emaan Rashidi, Caroline G. Tai et al.

2024 · 1 Zit.

Innovative Technologies in CNS Trials: Promises and Pitfalls for Recruitment, Retention, and Representativeness.

J. Gary Lutz, Abhishek Pratap, Eric J. Lenze et al.

2023 · 1 Zit.

Editorial: Ethical considerations of large language models: challenges and best practices

Pedro Elkind Velmovitsky, Luk Arbuckle, Paraskevi Papadopoulou

2026 · 0 Zit.

Análisis de coste-efectividad de la administración de darbepoetina alfa una vez cada tres semanas frente a su administración semanal en el tratamiento de la anemia inducida por quimioterapia

M. del Roser Guardia Riera, Ferran Pérez, Ana Vieta et al.

2008 · 0 Zit.

EE95 Value Comparison of BACT/ALERT®; VIRTUO® System Versus BD BACTEC™ FX Blood Culture System from a Provider Perspective

P. Krishnamurthy, P Anaya, S. Pinar Bilir et al.

2024 · 0 Zit.